Today, the Executive VP, General Counsel of Aduro BioTech (NASDAQ: ADRO), Templeman Blaine, sold shares of ADRO for $39.3K.
In addition to Templeman Blaine, 5 other ADRO executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Currently, Aduro BioTech has an average volume of 257.3K.
Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $17.50, reflecting a 159.3% upside.
The insider sentiment on Aduro BioTech has been negative according to 41 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes.
